Clinical trials: HIV 1 Infection
HIV-1 Infection
Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings
Several reports indicate that treatment failure due to HIV resistance or to adverse event-related discontinuation could compromise the effectiveness of scaling-up antiretroviral treatment (ART), especially when lack of access to…
- Trial name
- NAMSAL (NCT02777229)
- Testing
- Dolutegravir 50 mg, Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg, Efavirenz 400 mg
- Where
- 3 sites in Cameroon
- Volunteers
- 616 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine…
- Trial name
- NCT01910402
- Testing
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir
- Where
- 90 sites in United States, Argentina and 11 more
- Volunteers
- 499 people
- Sponsor
- ViiV Healthcare
HIV-1-infection
Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen
Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. The hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric…
- Trial name
- DOBINeuro (NCT04155554)
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide, Dolutegravir/lamivudine/abacavir
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
HIV-1-infection, Alcohol Drinking
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
Alcohol consumption is a critical factor in HIV treatment that significantly contributes to poor treatment-related outcomes. Randomized clinical trials (RCTs) of alcohol interventions for people with HIV (PWH) have had limited…
- Trial name
- NCT06648629
- Testing
- Acceptance and Commitment Therapy (ACT), Brief Alcohol Intervention
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Syracuse University
HIV-1 Infections, HIV Infections
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
Randomized, blinded, placebo-controlled trial to demonstrate if pre-exposure prophylaxis decreases HIV-1 acquisition among HIV-1 uninfected individuals within HIV-1 discordant couples.
- Trial name
- Partners PrEP (NCT00557245)
- Testing
- Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
- Where
- 9 sites in Kenya, Uganda
- Volunteers
- 4,758 people, healthy volunteers welcome
- Sponsor
- University of Washington
Human Immunodeficiency Virus (HIV)
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.
- Trial name
- NCT05197075
- Testing
- DRV/COBI FDC
- Where
- 6 sites in United States, South Africa and 1 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infections
Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2
To evaluate the safety and immunological effects of polyethylene glycolated-interleukin-2 (PEG-IL-2) on asymptomatic (without symptoms) HIV-seropositive patients who are taking zidovudine (AZT).
- Trial name
- NCT00002017
- Testing
- Interleukin-2, Polyethylene Glycolated
- Where
- United States
- Sponsor
- Rockefeller University
HIV-1/HBV Co-Infection
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate…
- Trial name
- Alliance (NCT03547908)
- Testing
- B/F/TAF, DTG, F/TDF
- Where
- 69 sites in United States, China and 12 more
- Volunteers
- 244 people
- Sponsor
- Gilead Sciences
Genital Herpes, HIV Infection
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1…
- Trial name
- NCT00527618
- Testing
- valacyclovir, acyclovir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
HIV-1-infection
Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.
Phase IIa, open clinical trial, pilot, single arm and proof of concept.
- Trial name
- NCT03539224
- Testing
- Dolutegravir (DTG), Lamivudine (3TC)
- Where
- 2 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
HIV-1-infection
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART)…
- Trial name
- ReSTART (NCT04388904)
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- The Crofoot Research Center, Inc.
HIV, HIV Infections
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
The purpose of this study is to look at the effect of daily herpes medication, valacyclovir, on HIV levels in the blood in persons who are HIV positive and do not have oral or genital herpes.
- Trial name
- NCT01059084
- Testing
- Valacyclovir
- Sponsor
- University of Washington
Human Immunodeficiency Virus
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
This is an investigator-initiated, two-year, randomized, controlled, single-center, open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to 3-drug HAART plus raltegravir for persons with acute and…
- Trial name
- UW PIC 330 (NCT00781287)
- Testing
- 3-drug anti-HIV therapy, Raltegravir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
HIV Infections
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of the HIV-1 reservoir in latently…
- Trial name
- NCT00808002
- Testing
- Raltegravir, Maraviroc, Tenofovir/Emtricitabine
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV-1 Infection
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
The purpose of this study is to determine whether a two-week course of disulfiram will reduce the HIV-1 latent reservoir in patients on highly active antiretroviral therapy (HAART).
- Trial name
- NCT01286259
- Testing
- Disulfiram
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV, HIV Infections
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and…
- Trial name
- NCT01818596
- Testing
- E/C/F/TAF
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 252 people
- Sponsor
- Gilead Sciences
HIV Infections
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.
- Trial name
- NCT00002420
- Testing
- Emivirine, Hydroxyurea, Delavirdine mesylate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
HIV-1-infection
ANRS 12406 EvvA Study
ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon.
- Trial name
- EvvA (NCT04593979)
- Where
- Cameroon
- Volunteers
- 289 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection, Methamphetamine-dependence
Effect of Methamphetamine on Residual Latent HIV Disease Study
The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation.
- Trial name
- EMRLHD (NCT03825536)
- Testing
- Oral Methamphetamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
HIV Infections
Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment
The purpose of this study is to test another way to control the amount of HIV in the blood (viral load). Studies show that stopping all anti-HIV drugs for a time before switching to new anti-HIV drugs may improve the response in…
- Trial name
- NCT00011128
- Testing
- Antiretroviral Treatment Interruption
- Where
- 30 sites in United States, Puerto Rico
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)